Table 4.
Aerosol and aerosolized cell therapy clinical trials.
| NCT No. | Title | Status | Company Name | Disease/Conditions | Route of Administration | Intervention/Mechanism Target | Results | Phase |
|---|---|---|---|---|---|---|---|---|
| NCT04313647 | A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes in Healthy Volunteers | Recruiting | Ruijin Hospital | Safety and Tolerance | Inhalation | 2 × 108, 4 × 108, 8 × 108, 16 × 108, 20 × 108 nano vesicles/3 mL to be administered to different sets of participants | N/A | 1 |
| NCT04473170 | Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 (SENTAD-COVID) | Completed | Abu Dhabi Stem Cells Center | COVID-19 | Inhalation | Participants were put into groups; group A received NHPBSC through jet nebulization and group B received standard care | N/A | 1 and 2 |
| NCT04389385 | COVID-19 Specific T cell-derived Exosomes (CSTC-Exo) | Active, Not recruiting yet | TC Erciyes University | COVID-19 | Inhalation | Participants will receive specific T cell-derived exosomes (CSTC-Exo) Aerosol inhalation of CSTC-Exo (2.0 × 108 nanovesicles / 3 mL at Day 1, 2, 3, 4 and 5 times daily | N/A | 1 |
| NCT04491240 | Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia (COVID-19EXO) | Enrolling by Invitation | State-Financed Health Facility “Samara Regional Medical Center Dinasty” | COVID-19 | Inhalation | 2 sets of participants will receive 0.5–2 × 1010 of nanoparticles (exosomes) | N/A | 1 and 2 |
| NCT04276987 | A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus | Not recruiting yet | Ruijin Hospital | COVID-19 | Inhalation | Participants will receive MSC-derived exosomes 5 times, aerosol inhalations of MSC-derived exosomes (2.0 × 108 nano vesicles/3 mL at Days 1, 2, 3, 4 and 5) | N/A | 1 |
N/A = Not yet available.